Lee Jeong-Woon, Lee Dabin, Shin Kyung-Ju, Son Keun Hong, Cho Je-Yoel
Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Korea.
BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.
Sci Rep. 2025 Jul 2;15(1):23404. doi: 10.1038/s41598-025-06296-z.
Circulating immune cells that have interacted with tumor tissue exhibit distinct characteristics compared to those in healthy individuals, providing potential biomarkers for tumor presence and malignancy. However, the epigenetic mechanisms governing these immune cells, particularly chromatin accessibility, remain poorly understood in cancer. In this study, we investigated chromatin accessibility and transcription factor binding in peripheral blood mononuclear cells from dogs with mammary gland tumors using ATAC-seq. Our analysis revealed significant changes in chromatin accessibility near genes associated with immune function, neuronal activity, and lipid metabolism. Notably, we identified CEBPD-bound peaks that were upregulated in PBMCs from tumor-bearing dogs and demonstrated that the transcription of their associated genes, CD47 and MAP4K4, was also elevated in monocytes under cancer co-culture conditions. This effect was mitigated following CRISPR interference of these regulatory regions. These findings highlight the crucial role of chromatin accessibility in shaping the immune response to cancer and suggest potential therapeutic targets for immune modulation.
与肿瘤组织相互作用的循环免疫细胞与健康个体的免疫细胞相比表现出明显不同的特征,为肿瘤的存在和恶性程度提供了潜在的生物标志物。然而,在癌症中,调控这些免疫细胞的表观遗传机制,尤其是染色质可及性,仍知之甚少。在本研究中,我们使用ATAC-seq技术研究了患有乳腺肿瘤的犬外周血单个核细胞中的染色质可及性和转录因子结合情况。我们的分析揭示了与免疫功能、神经元活动和脂质代谢相关基因附近的染色质可及性发生了显著变化。值得注意的是,我们鉴定出在患肿瘤犬的外周血单核细胞中上调的CEBPD结合峰,并证明在癌症共培养条件下,其相关基因CD47和MAP4K4在单核细胞中的转录也升高。对这些调控区域进行CRISPR干扰后,这种效应得到缓解。这些发现突出了染色质可及性在塑造对癌症的免疫反应中的关键作用,并为免疫调节提出了潜在的治疗靶点。
Cochrane Database Syst Rev. 2022-10-4
Cochrane Database Syst Rev. 2021-4-19
Front Cell Dev Biol. 2024-5-15
J Pharm Anal. 2024-4
J Allergy Clin Immunol. 2023-9